loader image
IMPORTANT SAFETY INFORMATION | PRESCRIBING INFORMATION

The only escape he should be experiencing

Evaluate effective testosterone suppression in your patients' GnRH therapy.

Measure

  • Many men experience testosterone breakthroughs while on androgen deprivation therapy (ADT)10-14
  • Testosterone breakthroughs produce PSA increases, mimicking progression to castrate-resistant prostate cancer (CRPC)10-14
  • Neglecting to assess testosterone will fail to identify levels above the desired target throughout the dosing period, including microsurges, and escapes15
  • Testosterone (T) levels should be measured regularly in men receiving ADT to ensure T suppression is being maintained to target5
  • Adding a testosterone test to regular prostate-specific antigen (PSA) assessment is simple to implement and can help address these concerns15

Measuring testosterone levels helps to assess if biochemical castration has been achieved and maintained.5

  • Many men experience testosterone breakthroughs while on androgen deprivation therapy (ADT)10-14
  • Testosterone breakthroughs produce PSA increases, mimicking progression to castrate-resistant prostate cancer (CRPC)10-14
  • Neglecting to assess testosterone will fail to identify levels above the desired target throughout the dosing period, including microsurges, and escapes15
  • Testosterone (T) levels should be measured regularly in men receiving ADT to ensure T suppression is being maintained to target5
  • Adding a testosterone test to regular prostate-specific antigen (PSA) assessment is simple to implement and can help address these concerns15

ACT

  • Trelstar lowered testosterone below castration levels*
  • Consistent testosterone and PSA suppression regardless of strength7
  • Fewer testosterone breakthroughs than Lupron® in a head-to-head study2

Prescribe TRELSTAR for reliable testosterone suppression.

  • TRELSTAR lowered testosterone below castration levels*
  • Consistent testosterone and PSA suppression regardless of strength7
  • Fewer testosterone breakthroughs than leuprolide acetate in a head-to-head study2

IS YOUR PROSTATE CANCER PATIENT Agonist Deficient?

Study Design

The 3.75 mg data are based on a 9-month, multicenter, parallel-group, blindly randomized, controlled clinical trial comparing TRELSTAR 3.75 mg to leuprolide acetate in patients with advanced (stage C/D) prostate cancer (N=284). Mean testosterone levels were calculated for months 2 to 9.

TRELSTAR can be ordered directly from our national specialty distributors which provide next business day delivery and other convenient benefits.

Order from AndaMEDS®

Call AndaMEDS at 1.855.468.5649, ext.74453.
If you already have a TRELSTAR account with AndaMEDS®, please click here or register at www.andameds.com.

Order from Besse Medical

Call Besse Medical at 800.543.2111.
If you already have a TRELSTAR account with Besse Medical, please click here or register at www.besse.com.

Order from CuraScriptSD®

Call CuraScriptSD® at 877.599.7748.
If you already have a TRELSTAR account with CuraScriptSD®, please click here or register at www.curascriptsd.com.

 

Order from Apexus®

For 340B entities order through the prime vendor, Apexus at www.apexus.com.

Thank you for visiting.

You are now leaving a Verity website. A link to a non-Verity website does not constitute an endorsement of the products or services offered by the non-Verity website, and Verity is not responsible for the content of any non-Verity website.

Healthcare Professionals

The information contained in this website is intended for US Healthcare professionals only.